A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.
New research from University of Iowa dispels the belief that pharmaceutical mergers lead to higher drug prices, showing a decrease in prices for generic drugs.